Compare Stocks → IRS Loophole Gives Americans An Escape From Inflation (From Birch Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDXNASDAQ:APLTNASDAQ:CERCNASDAQ:SLGLNASDAQ:TLC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$3.96-0.3%$3.56$1.42▼$11.97$233.24M1.51587,428 shs64,503 shsAPLTApplied Therapeutics$4.83$5.71$0.88▼$9.39$511.45M1.811.97 million shs32,913 shsCERCCerecor$15.94+4.6%$2.60$1.98▼$4.50$1.53B1.441.27 million shs222,087 shsSLGLSol-Gel Technologies$0.86-9.4%$1.05$0.79▼$4.20$23.87M1.3329,181 shs164 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics+2.58%-6.59%+42.81%+30.59%-62.15%APLTApplied Therapeutics-6.21%-12.18%-18.96%+93.98%+438.10%CERCCerecor0.00%+5.84%+259.01%+288.78%+465.25%SLGLSol-Gel Technologies-9.28%+1.40%-16.81%-24.17%-78.20%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%IRS Loophole Gives Americans An Escape From Inflation (Ad)In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.Request your info kit on gold nowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics1.9324 of 5 stars3.53.00.00.01.92.50.0APLTApplied Therapeutics4.752 of 5 stars4.53.00.04.72.63.30.6CERCCerecorN/AN/AN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies3.6338 of 5 stars3.85.00.00.03.31.71.3TLCTaiwan LiposomeN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics3.00Buy$9.33135.69% UpsideAPLTApplied Therapeutics3.00Buy$11.60140.17% UpsideCERCCerecorN/AN/AN/AN/ASLGLSol-Gel Technologies3.50Strong Buy$8.00833.60% UpsideTLCTaiwan LiposomeN/AN/AN/AN/ACurrent Analyst RatingsLatest TLC, SLGL, APLT, CERC, and ALDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.004/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/26/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/15/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/6/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $12.002/22/2024APLTApplied TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/22/2024APLTApplied TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/16/2024APLTApplied TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AAPLTApplied Therapeutics$9.99M51.20N/AN/A($0.20) per share-24.15CERCCerecor$6.70M228.42N/AN/A$0.22 per share72.45SLGLSol-Gel Technologies$1.55M15.40N/AN/A$1.67 per share0.51TLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)APLTApplied Therapeutics-$119.76M-$1.35N/AN/AN/AN/AN/A-275.83%5/9/2024 (Estimated)CERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/ASLGLSol-Gel Technologies-$27.24M-$1.01N/AN/AN/A-1,331.01%-61.52%-53.75%5/10/2024 (Estimated)TLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest TLC, SLGL, APLT, CERC, and ALDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023SLGLSol-Gel Technologies-$0.16-$0.17-$0.01-$0.17$0.27 million$0.45 million3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/A3/6/2024Q4 2023APLTApplied Therapeutics-$0.15-$0.33-$0.18-$0.33N/A($0.67) millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A6.646.64APLTApplied TherapeuticsN/A0.760.76CERCCerecor0.792.192.18SLGLSol-Gel TechnologiesN/A9.109.10TLCTaiwan Liposome0.673.013.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%APLTApplied Therapeutics98.31%CERCCerecor62.84%SLGLSol-Gel Technologies26.18%TLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics7.30%APLTApplied Therapeutics19.10%CERCCerecor45.70%SLGLSol-Gel Technologies66.51%TLCTaiwan LiposomeN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1558.90 million54.60 millionOptionableAPLTApplied Therapeutics25105.89 million85.66 millionOptionableCERCCerecor3196.01 millionN/ANot OptionableSLGLSol-Gel Technologies3627.86 million9.33 millionOptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableTLC, SLGL, APLT, CERC, and ALDX HeadlinesSourceHeadline‘7 Little Johnstons’ Season 14: How to watch episode 6 on TLC for freemsn.com - April 16 at 7:23 PMMonday: ‘Seeking Sister Wife’ Season 5, episode 7: How to watch TLC online for freecleveland.com - April 15 at 7:49 PMSee inside three-bed end terrace on sale for just £35k, but it needs serious TLCmsn.com - April 15 at 9:47 AMThe Disco Biscuits Nod To OutKast, TLC, Gucci Mane, & More In Atlanta [Video/Audio]liveforlivemusic.com - April 14 at 6:18 PMRico Wade, legendary Atlanta producer who worked with OutKast and co-wrote TLC's 'Waterfalls,' dies at 52msn.com - April 13 at 8:27 PMRico Wade, TLC ‘Waterfalls’ Cowriter and Southern Rap Trailblazer, Dies at 52thewrap.com - April 13 at 3:27 PMMorris continues new Brooks-TLC pleaobservertoday.com - April 12 at 8:34 AMTLC starts $27m upgradeaustralianageingagenda.com.au - April 11 at 8:17 PMTLC donates to Clatsop Animal Assistancedailyastorian.com - April 11 at 10:16 AMTLC Should Cancel ‘Sister Wives’ After Garrison Brown’s Suicidemsn.com - April 10 at 6:46 PMHow to watch TLC’s ‘Take My Tumor’ season 1, episode 2, stream for freepennlive.com - April 10 at 1:45 PMCrimestoppers seek tips on $500+ equipment theft from TLC Tree Service in Pananewschannel20.com - April 9 at 3:11 PM‘Seeking Sister Wife’ Season 5, episode 6: How to watch TLC online for freecleveland.com - April 8 at 7:40 PMHow to watch TLC’s ‘Seeking Sister Wife’ new episode free Monday, April 8masslive.com - April 8 at 7:40 PM'OutDaughtered' and 'Doubling Down With the Derricos' Finally Returning to TLC—See the Exclusive Teasersmsn.com - April 8 at 2:39 PMTLC is coming to the 2024 Wisconsin State Fair, with Jordin Sparks opening the concertmsn.com - April 8 at 2:39 PMFans Rejoice as ‘OutDaughtered’ and ‘Doubling Down With the Derricos’ Set to Premiere New Seasons on TLCmsn.com - April 8 at 2:39 PM2024 Wisconsin State Fair: TLC takes Main Stageyahoo.com - April 8 at 9:39 AM2024 Wisconsin State Fair: TLC takes Main Stage, Aug. 2fox6now.com - April 8 at 9:39 AMGoonya Fighter: First-Aid Boxes and some TLCkotaku.com - April 7 at 8:14 AMEastern Carolina woman looking for love on new season of TLC showwitn.com - April 6 at 10:36 AMOpen for Business: Lucid TLC Artssbj.net - April 5 at 2:27 PMTLC Tried To Replace The Duggars, But The New Reality Show Ended In Disastermsn.com - April 5 at 9:26 AMExmouth's former railway carriage up for sale - but it needs some TLCuk.news.yahoo.com - April 4 at 8:23 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Applied TherapeuticsNASDAQ:APLTApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.CerecorNASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Sol-Gel TechnologiesNASDAQ:SLGLSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Taiwan LiposomeNASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.